Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Postoperative circulating tumor DNA could guide CRC adjuvant treatment

The large, ongoing CIRCULATE-Japan trial is investigating the role of circulating tumor DNA (ctDNA)-based molecular residual disease testing in patients with resectable colorectal cancer after radical surgery. An interim analysis of GALAXY, a prospective, observational arm of CIRCULATE-Japan, establishes ctDNA as a prognostic and predictive biomarker.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Fig. 1: ctDNA-based molecular residual disease testing is predictive of response to adjuvant chemotherapy in surgically treated patients with CRC.

References

  1. Yoshino, T. et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer. Ann. Oncol. 32, 1496–1510 (2021). This publication reports the current clinical practice guidelines for CRC.

    Article  CAS  Google Scholar 

  2. O’Connor, E. S. et al. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol. 29, 3381–3388 (2011). This study demonstrates a lack of overall survival benefit from adjuvant chemotherapy for patients with stage II CRC.

    Article  Google Scholar 

  3. Sobrero, A. F. et al. A new prognostic and predictive tool for shared decision making in stage III colon cancer. Eur. J. Cancer. 138, 182–188 (2020). This study highlights variability in treatment outcomes among patients with stage III CRC.

    Article  CAS  Google Scholar 

  4. Taniguchi, H. et al. CIRCULATE-Japan: circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer. Cancer Sci. 1, 14926 (2021). This publication discusses the clinical trial protocol associated with CIRCULATE-Japan.

    Google Scholar 

  5. Kasi, P. M. et al. Impact of circulating tumor DNA-based detection of molecular residual 414 disease on the conduct and design of clinical trials for solid tumors. JCO Precis. Oncol. 6, e2100181 (2022). A review article that presents the clinical utility of ctDNA and its effect on clinical trial design.

    Article  Google Scholar 

Download references

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This is a summary of: Kotani, D. A. et al. Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer. Nat. Med. https://doi.org/10.1038/s41591-022-02115-4 (2023).

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Postoperative circulating tumor DNA could guide CRC adjuvant treatment. Nat Med 29, 39–40 (2023). https://doi.org/10.1038/s41591-022-02119-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-022-02119-0

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing